Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Vanguard Total Stock Mkt Idx Inv

Vanguard Institutional 500 Index Trust

American Funds American Mutual A

Capital Group American Mutual Comp

Vanguard Dividend Growth Inv

The Health Care Select Sector SPDR® ETF

American Funds Capital World Gr&Inc A

Capital Group World Growth & Inc Cmp

American Funds Capital Income Bldr A

Vanguard Institutional Index I

Vanguard Dividend Appreciation ETF

State St S&P 500® Indx SL Cl III

SPDR® S&P 500® ETF Trust

Fidelity 500 Index

iShares Core S&P 500 ETF

American Funds Invmt Co of Amer A

Capital Group Investment Co of Amer Comp

American Funds Washington Mutual A

Capital Group Wash Mutual Invtrs Comp

Vanguard Value Index Inv

Vanguard Group Inc

BlackRock Inc

Northern Trust Corp

Wells Fargo & Co

Legal & General Group PLC

Polen Capital

State Farm Mutual Automobile Ins Co

Bank of New York Mellon Corp

Massachusetts Financial Services Company

Charles Schwab Investment Management Inc

Ameriprise Financial Inc

Deutsche Bank AG

State Street Corp

Capital Research & Mgmt Co - Division 3

Capital Research Global Investors

Geode Capital Management, LLC

Morgan Stanley - Brokerage Accounts

JPMorgan Chase & Co

Wellington Management Company LLP

NORGES BANK

Abbott Laboratories

Mr. Robert B. Ford

Chairman of the Board, President & CEO

Mr. Philip P. Boudreau

CFO & Executive VP of Finance

Mr. Hubert L. Allen J.D.

Executive VP, General Counsel & Secretary

Mr. Daniel Gesua Sive Salvadori

Executive VP and Group President of Established Pharmaceuticals & Nutritional Products

ABT's next earnings is on January 22, 2025 (Before Market Open)

ABT's latest dividend is 0.55 USD on July 15, 2024

Abbott Laboratories (ABT) Stock Analysis, Discussion Forum and Financial Metrics - NYSE Exchange

Abbott Laboratories (ABT) Earnings Report Date and History | NYSE

ABT's next earnings is on January 22, 2025 (Before Market Open)

When is the earnings report for ABT?

ABT Earnings History

ABT's latest dividend is 0.55 USD on July 15, 2024

ABT Stock Discussion Forum and Message Board

News for NYSE: ABT